Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors DOI Creative Commons
Kangning Zhao, Jinlong Zhang, Lin Zhou

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 25, 2024

Scutellaria baicalensis has been used for the treatment of digestive system disorders thousands years in China and other regions. Modern research have revealed its therapeutic efforts tumors. Thus, to review updated progress S. main flavonoids tumors past 10 years, this article summarized effect molecular mechanisms 5 on oral cavity, esophagus, stomach, colon, liver, pancreas by inhibiting tumor cell proliferation, inducing autophagy, stimulating immune response, increasing drug sensitivity. In conclusion, could be applied treat with different type methods.

Language: Английский

How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force DOI Creative Commons
Christelle de la Fouchardière, Antonella Cammarota, Magali Svrcek

et al.

Cancer Treatment Reviews, Journal Year: 2025, Volume and Issue: 134, P. 102890 - 102890

Published: Feb. 1, 2025

In less than a decade, immune checkpoint inhibitors (ICIs) have transformed the management of mismatch repair-deficient (dMMR) and microsatellite instability-high (MSI) cancers. However, beyond colorectal cancer (CRC), much evidence is mostly derived from non-randomized phase II studies or post-hoc analyses broader clinical trials. dMMR/MSI tumours represent specific subgroup gastro-esophageal adenocarcinomas (GEA), accounting for approximately 9 % cases, with higher prevalence in early-stage compared to advanced-stage disease older female patients. These are predominantly sporadic, often linked MLH1 promoter methylation, rarely exhibit HER2 overexpression/ERBB2 amplification other oncogenic drivers. The treatment landscape early stage GEA likely change substantially soon, as ICIs shown high pathological complete response (pCR) rates small trials, raising questions on optimisation neoadjuvant therapy, paving way organ preservation. standard untreated patients advanced chemotherapy + ICI irrespectively PDL-1 status. role chemotherapy-free regimen consisting CTLA-4 plus PD-1 remains undetermined. This review addresses these emerging questions, offering expert opinions insights into future therapeutic GEA.

Language: Английский

Citations

2
Deciphering the impact of aggregated autophagy-related genes TUBA1B and HSP90AA1 on colorectal cancer evolution: a single-cell sequencing study of the tumor microenvironment DOI Creative Commons

Qianping Xu,

Chao Liu, Hailin Wang

et al.

Discover Oncology, Journal Year: 2024, Volume and Issue: 15(1)

Published: Sept. 11, 2024

Language: Английский

Citations

6
Canadian consensus for the assessment and testing of Lynch syndrome DOI Creative Commons
Melyssa Aronson, Laura Palma, Kara Semotiuk

et al.

Journal of Medical Genetics, Journal Year: 2025, Volume and Issue: unknown, P. jmg - 110465

Published: March 12, 2025

Background Lynch syndrome (LS) is an autosomal dominant cancer predisposition caused by a germline pathogenic variant, or epigenetic silencing, of mismatch repair (MMR) gene, leading to wide spectrum with gene-specific penetrance. Ascertainment, assessment and testing LS individuals complex. A Canadian national guideline needed ensure equitable access patient care across the country. Methods The Syndrome (CDN-LS) working group was formed in 2021, consisting 37 multidisciplinary experts partners. To formulate consensus statements, environmental scan, clinical survey literature review were undertaken. e-Delphi method used reach statements among CDN-LS group. Results voted on 21 18 adopted over 80% agreement, including 16 that had 90% agreement. These provide comprehensive guidelines universal MMR reflex testing, cascade tumour ( MLH1 promoter methylation, BRAF , somatic MMR), therapeutics advocacy. Conclusion This first for providing guidance genetic specialists, laboratories, primary providers healthcare caring patients LS. It endorsed College Medical Genetics Association Genetic Counsellors. are presented as model standard improves health services Future work should include surveillance, goal harmonise all provincial territorial authorities.

Language: Английский

Citations

0
Clinical and Pathologic Response to Neoadjuvant Immunotherapy in DNA Mismatch Repair Protein-Deficient Gastroesophageal Cancers DOI
Adrienne B. Shannon, Rutika Mehta, Shaffer Mok

et al.

Annals of Surgical Oncology, Journal Year: 2024, Volume and Issue: 31(13), P. 8616 - 8626

Published: Aug. 17, 2024

Language: Английский

Citations

2
Scutellaria baicalensis and its flavonoids in the treatment of digestive system tumors DOI Creative Commons
Kangning Zhao, Jinlong Zhang, Lin Zhou

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 25, 2024

Scutellaria baicalensis has been used for the treatment of digestive system disorders thousands years in China and other regions. Modern research have revealed its therapeutic efforts tumors. Thus, to review updated progress S. main flavonoids tumors past 10 years, this article summarized effect molecular mechanisms 5 on oral cavity, esophagus, stomach, colon, liver, pancreas by inhibiting tumor cell proliferation, inducing autophagy, stimulating immune response, increasing drug sensitivity. In conclusion, could be applied treat with different type methods.

Language: Английский

Citations

1